SRPHC153049-CORONARY DRUG ELUTING STENTS (1) SINGLE WIRE TECHNOLOGY ON COBALT BASED ALLOY PLATFORM (2) STENT WITH COATING OF BIOLINX POLYMER CARRIER FOR ACTIVE DRUG ZOTAROLIMUS SHOWN TO BE EFFECTIVE IN PREVENTING NEO-INTIMAL HYPERPLASIA) (3) STENT DIAMETER SHOULD BE FROM 2.25 MM TO 4 MM AND LENGTH OF THE STENT FROM 12MM TO 38 MM. (4) THE STRUT THICKNESS SHOULD BE 81 MICRON OR LESS. (5) STENT DELIVERY SYSTEM SHOULD BE MONORAIL (SINGLE OPERATOR EXCHANGE OR RAPID EXCHANGE). (6) STENT SHOULD BE COMPATIBLE WITH 5FR GUIDING CATHETER (7) STENT DESIGN SHOULD BE OPEN CELL TYPE. (8) STENT SHOULD BE APPROVED BY DCGI. THE COPY OF DCGI APPROVAL SHOULD BE ENCLOSED IN THE TENDER BID. (9) FIVE YEARS LONG TERM EFFICACY AND SAFETY OF THE STENT IN TERMS OF TARGET VESSELREVASCULARISATION (TVR) AND IN-SITU THROMBOSIS (IST) SHOULD BE DOCUMENTED / PUBLISHED IN PEER REVIEWED SCIENTIFIC JOURNALS.(10) THE DOCUMENTS PERTAINING TO THE EFFICACY AND SAFETY OF THE STENT SHOULD BE ENCLOSED FOR THE BRAND THAT IS OFFERED IN THE TENDER BID (11) THE MANUFACTURER/SUPPLIER SHOULD SUBMIT PROOF OF SUPPLY OF THE STENT TO A MAJOR GOVERNMENT INSTITUTE. UNIT:NO[Quantity Tolerance (+/-): 5 %age , Item Category : Normal , Total PO value variation Permitted: Max 8 lacs ] ]
We takes all possible care for accurate & authentic tender information, however Users
are requested to refer Original source of Tender Notice / Tender Document published by
Tender Issuing Agency before taking any call regarding this tender.
